All In Biotech

NDA 208562 · Hikma

Voriconazole

Voriconazole · Intravenous, Injection · Azole Antifungal

Last checked: Nov 20, 2026Latest source record: Apr 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Mar 9, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

153

39 Phase 3, 14 recruiting

FAERS reports

22,090

20,722 serious, 6,438 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 11, 2023.

Voriconazole for injection is an azole antifungal indicated for use in the treatment of adults and pediatric patients aged 12 to 14 years weighing greater than or equal to 50 kg and those aged 15 years and older regardless of body weight with: Invasive aspergillosis ( 1.1 ) Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.3 ) 1.1 Invasive Aspergillosis Voriconazole for injection is indicated in adults and pediatric patients (aged 12 to 14 years weighing greater than or equal to 50 kg and those aged 15 years and older regardless of body weight) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus . There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies (14.1) and Microbiology (12.4) ]. 1.2 Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections Voriconazole for injection is indicated in adult and pediatric patients (aged 12 to 14 years weighing greater than or equal to 50 kg and those aged 15 years and older regardless of body weight) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see Clinical Studies (14.2) and Microbiology (12.4) ]. 1.3 Scedosporiosis and Fusariosis Voriconazole for injection is indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii ) and Fusarium spp ....

Mechanism: Voriconazole is an antifungal drug [see Microbiology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 9, 2017 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
2 products under this application
  • VORICONAZOLE · VORICONAZOLE 200MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
  • VORICONAZOLE · VORICONAZOLE 200MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Voriconazole" as an intervention, any sponsor and status, largest first.

All 153 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,031
  • off label use2,121
  • drug interaction2,063
  • pyrexia1,074
  • pneumonia911
  • bronchopulmonary aspergillosis897
  • condition aggravated879
  • aspergillus infection866
  • febrile neutropenia756
  • death727
  • respiratory failure692
  • multiple organ dysfunction syndrome667

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200489
2005108
2006113
2007193
2008210
2009294
2010359
2011388
2012429
2013495
2014459
2015570
2016798
20171,417
20181,785
20191,949
20201,988
20211,919
20221,945
20231,831
20241,790
20251,733
20261,227

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Voriconazole* (Voriconazole)

2024 spending

$14.3M

Beneficiaries

12,684

37,376 claims

Per beneficiary

$1,131

$5.69 per unit

View as table
YearSpending
2020$30,512,600
2021$20,611,160
2022$19,192,110
2023$18,801,407
2024$14,346,156

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 407 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.